ISOCYPTOX

A NOVEL CELL-BASED AND READY-TO-USE CONCEPT FOR IN VITRO EVALUATION OF BIOTRANSFORMATION-MEDIATED METABOLIC TOXICITY

IsoCyp™–Tox Experimental Data: Curve fitting of IC50 values of test compounds



Fig.1



Fig.2



Fig.3

Wild type hepatic human cell line (HepG2) transiently transduced with human CYP450 isoforms 1A2, 2E1, 3A4 and 2A6. For endpoint WST-1 assay, figures show, specific bioactivation in 3A4 and, to a lesser extend, in 1A2 for Aflatoxin B1 (Fig.1); parent compound toxicity for sodium diclofenac (Fig.2) and general toxicity for potassium bromate (nonmediated by CYP450 specific metabolism) (Fig.3)

FOUR SIMPLE STEPS OF IsoCyp™–Tox

RECEIVE	LIQUIFY	APPLY	ASSAY
Ready-to-use HepG2 transiently transduced cell line	Liquefying of solid shipping medium at 37ºC	Incubation with test compound	Assessment of a simple toxicity end point

Formats

IsoCyp™-Tox standard kit containing 6 x 96-well plates, Ref. KRECE-ICT50:

- 5 x 96-well plates of HepG2 transduced with single CYP450 isoform, including 1 x 96-well plate for each CYP450 isoform (3A4, 2E1, 1A2, 2A6 and 2C9)
- 1 x 96-well control plate of HepG2 untransduced (metabolic incompetent cells)

IsoCyp™-Tox individual CYP450 kit containing 2 x 96-well plates:

- 1 x 96-well plate of HepG2 transduced with single CYP450 of interest:

3A4: Ref. KRECE-ICT51, 2E1: Ref. KRECE-ICT52, 1A2: Ref. KRECE-ICT53, 2A6: Ref. KRECE-ICT54 or 2C9: Ref. KRECE-ICT55

- 1 x 96-well control plate of HepG2 untransduced (metabolic incompetent cells)

READYCELL
easing your screening

sales kirkleesbio.com
Phone: 01484 365369
www.kirkleesbio.com

KirkleesBIO
Kirklees Biosciences Ltd